8-K: SS Innovations International to List on Nasdaq Capital Market, Shares to Trade Under Ticker SSII

SS Innovations International, Inc. announces its common stock has been approved for listing on the Nasdaq Capital Market, with trading expected to commence on April 25, 2025, under the ticker symbol SSII.

Summary

• SS Innovations International, Inc. (SSII) announced its common stock has been approved for listing on the Nasdaq Capital Market.
• Trading is expected to begin on April 25, 2025, under the ticker symbol SSII.
• The company develops surgical robotic technologies.
• SSII's Chairman and CEO, Dr. Sudhir Srivastava, believes the Nasdaq uplisting will enhance market awareness, improve transparency, expand the investor base, and increase share liquidity.
• The company is expanding globally beyond India into Nepal, Ecuador, Guatemala, the Philippines, Indonesia, Sri Lanka, and Ukraine.
• SSII plans a strategic entry into Europe and the United States.
• The company is pursuing EU CE Mark and U.S. FDA approval for its SSi Mantra surgical robotic system, anticipated in late 2025 and early 2026, respectively.
• SSII has installed 80 SSi Mantra systems in 75 hospitals across India and other countries.
• Over 3,500 surgeries have been performed using the SSi Mantra, including over 195 robotic cardiac surgeries with zero reported device-related mortality, injuries, or complications.
• SSII is the first and only company in India to receive CDSCO approval for telesurgery and tele-proctoring procedures.
• The company has performed 16 telesurgeries using SSi Mantra, including the world's first robotic cardiac telesurgeries over distances up to 1,200 miles.
• SSII reported revenue for the year ended December 31, 2024, of $20.6 million, a 251% increase from $5.9 million in 2023.
• Gross margin increased to 40.9% in 2024 from 12.3% in 2023.

Sentiment

Score: 8

Explanation: The announcement is positive due to the Nasdaq uplisting, significant revenue growth, and improved gross margins. The company's expansion plans and regulatory approvals also contribute to the positive sentiment.

Positives

• The Nasdaq uplisting is expected to enhance market awareness, improve transparency, expand the investor base, and increase share liquidity.
• The company has experienced significant revenue growth, with a 251% increase in 2024.
• Gross margins have improved substantially, indicating better profitability.
• The SSi Mantra system has been clinically validated with a large number of surgeries performed and no device-related mortality, injuries, or complications reported in cardiac surgeries.
• SSII has received regulatory approval in India for telesurgery and tele-proctoring, enabling remote surgical procedures.

Risks

• The company's future financial performance is subject to risks and uncertainties.
• The company's ability to obtain EU CE Mark and U.S. FDA approval for its SSi Mantra surgical robotic system is not guaranteed and is subject to regulatory processes.
• Global expansion plans may face challenges and delays.

Future Outlook

The company anticipates EU CE Mark approval in late 2025 and U.S. FDA approval in early 2026 for its SSi Mantra surgical robotic system and plans to expand globally beyond India, including strategic entry into Europe and the United States.

Management Comments

• Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations, commented that the Nasdaq uplisting marks an exciting milestone and reflects the team's achievements in building a world-class robotic surgery technology platform.
• Dr. Srivastava believes the uplisting will enhance market awareness, improve transparency, expand the investor base, and increase share liquidity.

Industry Context

The announcement positions SS Innovations to compete more effectively in the global surgical robotics market, which is dominated by companies like Intuitive Surgical. The focus on affordability and accessibility could allow SS Innovations to capture a significant share of the market, particularly in developing countries.

Comparison to Industry Standards

• Intuitive Surgical, the maker of the Da Vinci surgical robot, is the market leader in surgical robotics.
• SS Innovations' focus on affordability and accessibility differentiates it from Intuitive Surgical, which has a higher price point.
• The company's telesurgery capabilities, with CDSCO approval in India, provide a competitive advantage.
• The reported gross margin of 40.9% is lower than Intuitive Surgical's gross margin, which is typically above 70%.

Stakeholder Impact

• Shareholders are likely to benefit from increased market awareness and potential share liquidity due to the Nasdaq listing.
• The company's expansion plans may create new job opportunities.
• Patients could benefit from more affordable and accessible robotic surgery options.
• Hospitals may benefit from the cost-effective SSi Mantra system.

Next Steps

• Commencement of trading on Nasdaq on April 25, 2025.
• Pursuing EU CE Mark and U.S. FDA approval for the SSi Mantra system.
• Global expansion into Nepal, Ecuador, Guatemala, the Philippines, Indonesia, Sri Lanka, and Ukraine.
• Strategic entry into Europe and the United States.

Key Dates

Keywords

SS Innovations International, Nasdaq, SSII, surgical robotics, SSi Mantra, telesurgery, FDA approval, CE Mark, revenue growth, gross margin